FENNEC PHARMACEUTICALS INC. 10-Q

Item 5. Other Information. Insider Trading Arrangements and Policies During the quarter ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulations S-K. ​ Press Release On May 14, 2024, we issued a press release announcing our financial results for the quarter ended March 31, 2024. A copy of the news release is attached to this Quarterly Report as Exhibit 99.1. The press release is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release. ​ Item 6. Exhibits ​ Exhibit No. Description ​ ​ ​ 10.1 1 ​ License and Supply Agreement, dated March 15, 2024, between Fennec Pharmaceuticals, Inc. and Norgine Pharma UK Limited. ​ ​ ​ 31.1 ​ Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith). ​ 31.2 ​ Certification of Chief Financial Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith). ​ 32.1 ​ Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith). ​ 99.1 ​ Press Release for Quarter Ended March 31, 2024 (filed herewith). ​ 101.INS* ​ Inline XBRL Instance Document ​ ​ ​ 34 Table of Contents 101.SCH* ​ Inline XBRL Taxonomy Extension Schema Document ​ ​ ​ 101.CAL* ​ Inline XBRL Taxonomy Extension Calculation Linkbase Document ​ ​ ​ 101.DEF* ​ Inline XBRL Taxonomy Extension Definition Linkbase Document ​ ​ ​ 101.LAB* ​ Inline XBRL Taxonomy Extension Label Linkbase Document ​ ​ ​ 101.PRE* ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document ​ ​ ​ 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101) 1. In accordance with Item 601(b)(10)(iv) of Regulation S-K, certain provisions and terms of this exhibit have been redacted. Fennec will provide an unredacted copy of the exhibit on a supplemental basis to the SEC or its staff upon request. ​ ​ ​ ​ ​ 35 Table of Contents SIGNATURES Pursuant to requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ Fennec Pharmaceuticals Inc. Date: May 14, 2024 By: /s/ Rostislav Raykov Rostislav Raykov Chief Executive Officer (principal executive officer) Date: May 14, 2024 By: /s/ Robert Andrade Robert Andrade Chief Financial Officer (principal financial and chief accounting officer) ​ ​ ​ ​ ​ 36